Impact Of RA Therapy Compliance On Patient-Reported Outcomes

Pfizer396 enrolled

Overview

Several observational studies have evaluated the comparative treatment costs associated with each agent, particularly those within the anti-TNF class, but few have evaluated the impact of therapy compliance, persistence, treatment patterns on patient reported outcomes, healthcare utilization and costs, using a provider database. This study is designed to fill in this information gap.

Cohort observational

Study Type

OBSERVATIONAL

Enrollment

396

Conditions

Rheumatoid Arthritis

Interventions

tDMARDsDRUG

Traditional DMARDs for RA

biodmardsDRUG

Biologic DMARDs

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adults with moderate to severe RA who are currently using a DMARD Exclusion Criteria: * Psoriatic Arthritis (PsA), Psoriasis (PsO), SSystemic Lupus Erythematosus (SLE), Non-Disease modifying anti-rheumatic disease (non-DMARD) use

Outcomes

Primary Outcomes

HAQ

Time frame: 12 months

36-Item Short-Form Health Survey (SF-36)

Time frame: 12 months

Secondary Outcomes

Compliance

Time frame: 12 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.